A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

Study Identifier:

405-201-00056

ClinicalTrials.gov Identifier:

NCT05113953

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

Eating Disorder

Study Drug

Drug: Centanafadine
Drug: Placebo

Date

Dec 2021 - Aug 2022

Phase 1/2

Phase 2/3

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams \[mg\] and 400 mg total daily dose \[TDD\]) compared with placebo in adults with moderate to severe binge eating disorder (BED).

Study Locations

Location

Status

Location

NoesisPharma, LLC

Phoenix, Arizona, United States, 85016

Status

N/A

Location

Southern California Research LLC

Beverly Hills, California, United States, 90210

Status

N/A

Location

Pharmacology Research Institute - San Fernando Valley

Encino, California, United States, 91316

Status

N/A

Location

Collaborative Neuroscience Research, LLC

Garden Grove, California, United States, 92845

Status

N/A

Location

Pacific Clinical Research Management Group LLC

Upland, California, United States, 91786

Status

N/A

Location

Mountain View Clinical Research, LLC

Denver, Colorado, United States, 80209

Status

N/A